Skip to main content
Equibles

KREBSBIO · Krebs Biochemicals and Industries Limited · Financials

Use KREBSBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KREBSBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
58.88 INR -0.12 (-0.20%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 373 Avg daily vol (3M) 3962

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
237.32M -45.2%
FY2026 Revenue FY2018–FY2026
Net Income
-169.33M +37.1%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
-19.21M +75.7%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
INR 268.57M 237.32M 433.12M 504.22M 521.34M 529.41M 537M 334.12M 477.58M 337.79M
INR 63.94M 64.23M 66.89M 67.66M 65.59M 62.97M 51.24M 46.79M 44.02M 41.5M
INR 74.85M 70.86M 59.14M 46.89M 29.73M 53.91M 62.79M 59.28M 62.38M 51.65M
INR -133.49M -169.33M -269.24M -197.28M -246.92M -445.27M -283.59M -288.72M -200.12M -178.25M
INR 0 0 153K 0 0 0 0 0 0 0
INR -133.49M -169.33M -269.39M -197.28M -246.92M -445.27M -283.59M -288.72M 0 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 0 in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.